United Health Products, Inc. Files 10-Q for Q1 2024

TL;DR

<b>United Health Products, Inc. has filed its Q1 2024 10-Q report.</b>

AI Summary

United Health Products, Inc. (UEEC) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Filing is a 10-Q for the period ending March 31, 2024. Company name is United Health Products, Inc. (formerly United EcoEnergy Corp.). Incorporated in Nevada, fiscal year ends December 31. Business address: 526 Commerce Circle, Ste. #120, Mesquite, NV 89027. Phone number: 475-755-1005.

Why It Matters

For investors and stakeholders tracking United Health Products, Inc., this filing contains several important signals. This filing provides an update on the company's financial performance and operational status for the first quarter of 2024. It allows investors and stakeholders to assess the company's current financial health and strategic direction.

Risk Assessment

Risk Level: low — United Health Products, Inc. shows low risk based on this filing. The filing is a standard quarterly report (10-Q) and does not contain immediate, significant financial or operational disclosures that would alter the risk profile.

Analyst Insight

Review the detailed financial statements and management discussion within the 10-Q to understand the company's performance and outlook.

Key Numbers

• 2024-03-31 — Reporting Period End Date (10-Q filing)
• 2024-05-09 — Filing Date (10-Q filing)
• 3842 — Standard Industrial Classification (Orthopedic, Prosthetic & Surgical Appliances & Supplies)

Key Players & Entities

• United Health Products, Inc. (company) — Filer name
• UEEC (company) — Ticker symbol
• United EcoEnergy Corp. (company) — Former company name
• NV (location) — State of incorporation
• Mesquite (location) — Business address city
• 89027 (postal_code) — Business address zip
• 475-755-1005 (phone_number) — Business phone
• 2024-03-31 (date) — Reporting period end date

FAQ

Industry Context

The company operates in the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry.

Regulatory Implications

This is a standard SEC filing (10-Q) required for publicly traded companies to report quarterly financial information.

What Investors Should Do

1. Review the full 10-Q document for detailed financial statements.
2. Analyze the Management's Discussion and Analysis section for operational insights.
3. Check for any new disclosures regarding business developments or risks.

Key Dates

• 2024-03-31: Quarterly Period End — End of the reporting period for the 10-Q filing.
• 2024-05-09: Filing Date — Date the 10-Q report was officially submitted to the SEC.

Year-Over-Year Comparison

This is the Q1 2024 10-Q filing, providing an update from previous filings.

Key Financial Figures

• $0 — e notes payable was $ 19,231 (including $0 of debt discount amortization related t
• $0.35 — rity date at a price that is lower than $0.35 per share, the conversion price shall b

Filing Documents

• ueec_10q.htm (10-Q) — 539KB
• ueec_ex311.htm (EX-31.1) — 9KB
• ueec_ex312.htm (EX-31.2) — 9KB
• ueec_ex321.htm (EX-32.1) — 4KB
• ueec_ex322.htm (EX-32.2) — 4KB
• 0001477932-24-002630.txt (&nbsp;) — 2751KB
• ueec-20240331.xsd (EX-101.SCH) — 33KB
• ueec-20240331_lab.xml (EX-101.LAB) — 202KB
• ueec-20240331_cal.xml (EX-101.CAL) — 33KB
• ueec-20240331_pre.xml (EX-101.PRE) — 163KB
• ueec-20240331_def.xml (EX-101.DEF) — 91KB
• ueec_10q_htm.xml (XML) — 267KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) Condensed Balance Sheets as of March 31, 2024 (unaudited) and December 31, 2023 3 Condensed Statements of Operations for the Three Months Ended March 31, 2024 and March 31, 2023 (unaudited) 4 Condensed Statement of Stockholders' Deficiency for the Three Months Ended March 31, 2024 and March 31, 2023 (unaudited) 5 Condensed Statements of Cash Flows for the Three Months Ended March 31, 2024 and March 31, 2023 (unaudited) 7 Notes to Condensed Financial Statements (unaudited) 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 17 Item 3.

Quantitative and Qualitative Disclosures

Quantitative and Qualitative Disclosures 23 Item 4.

Controls and Procedures

Controls and Procedures 23

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 24 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24 Item 3. Defaults Upon Senior Securities 24 Item 4. Mine Safety Disclosures 24 Item 5. Other Information 24 Item 6. Exhibits and Reports on Form 8-K 25

SIGNATURES

SIGNATURES 27 2 Table of Contents UNITED HEALTH PRODUCTS, INC. Condensed Balance Sheets March 31, December 31, 2024 2023 (Unaudited) ASSETS Current Assets Cash and cash equivalents $ 80,882 $ 95,420 Inventory 33,598 33,598 Prepaid and other current assets 15,172 22,804 Total current assets 129,652 151,822 Deferred offering costs - 21,051 Operating lease right-of-use asset 69,430 76,520 Security deposit 2,850 2,850 Patents, net 31,388 32,400 TOTAL ASSETS $ 233,320 $ 284,643 Current Liabilities Accounts payable and accrued expenses $ 975,271 $ 987,567 Accrued liabilities - related parties 275,956 226,475 Operating lease liability - current 30,277 28,838 Convertible notes payable, net of debt discount 207,500 207,500 Convertible notes payable – related party, net of debt discount 500,000 500,000 Total current liabilities 1,989,004 1,950,380 Operating lease liability – long-term 40,306 48,489 TOTAL LIABILITIES 2,029,310 1,998,869 Commitments and Contingencies - - Stockholders' Deficit Series A Convertible Preferred Stock - $ 0.001 par value, 1,000,000 shares Authorized and 0 shares issued and outstanding - - Common Stock - $ 0.001 par value, 300,000,000 shares Authorized, 246,833,222 and 244,783,222 shares issued and outstanding at March 31, 2024 and December 31, 2023 246,833 244,783 Additional Paid-In Capital 75,108,325 74,740,201 Accumulated Deficit ( 77,151,148 ) ( 76,699,210 ) Total Stockholders' Deficit ( 1,795,990 ) ( 1,714,226 ) TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $ 233,320 $ 284,643 See notes to unaudited condensed financial statements. 3 Table of Contents UNITED HEALTH PRODUCTS, INC. Condensed Statements of Operations (Unaudited) For the Three Months Ended March 31, 2024 2023 Revenues $ - $ - Operating Costs and Expenses Selling, general and administrative expenses 309,543 835

View Full Filing

View this 10-Q filing on SEC EDGAR